Yelena Iglanova
Surgical · Manhasset, NYNPI 1033289194
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,663, more than ten times the $213 reported in 2022. Among surgical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$795
- E.r. Squibb & Sons, L.L.C.$608
- Corium, LLC$573
- Teva Pharmaceuticals USA, Inc.$564
- Alkermes, Inc.$526
- Lundbeck LLC$508
- plus $3K from 21 others
What the payments were for
- Food & beverage$6,85199%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $795 |
| E.r. Squibb & Sons, L.L.C. | 36 | $608 |
| Corium, LLC | 39 | $573 |
| Teva Pharmaceuticals USA, Inc. | 33 | $564 |
| Alkermes, Inc. | 32 | $526 |
| Lundbeck LLC | 39 | $508 |
| Otsuka America Pharmaceutical, Inc. | 32 | $490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $358 |
| Neurocrine Biosciences, Inc. | 13 | $292 |
| Idorsia Pharmaceuticals US Inc | 12 | $277 |
| Bausch Health US, LLC | 14 | $255 |
| Johnson & Johnson | 12 | $243 |
| Supernus Pharmaceuticals, Inc. | 8 | $242 |
| Inari Medical, Inc. | 1 | $213 |
| Vanda Pharmaceuticals Inc. | 9 | $198 |
| Axsome Therapeutics, Inc. | 3 | $183 |
| Indivior Inc. | 6 | $110 |
| Almatica Pharma LLC | 5 | $91 |
| Tris Pharma Inc | 4 | $71 |
| Ironshore Pharmaceuticals Inc. | 3 | $62 |
| Vertical Pharmaceuticals, LLC | 3 | $57 |
| Biogen | 3 | $52 |
| Avion Pharmaceuticals | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$213
- CT THROMBECTOMY SYSTEM KIT$213
- Auvelity$133
- QELBREE$125
- COBENFY$122
- QUVIVIQ$109
How this compares
$6,892 in reported general payments places this provider in the 95th percentile of 1,544 surgical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 63 | $101,576 |
| SpravatoEsketamine Hcl | 36 | $64,132 |
| CaplytaLumateperone Tosylate | 11 | $21,159 |
| TrintellixVortioxetine Hydrobromide | 27 | $20,905 |
| OzempicSemaglutide | 16 | $15,807 |
| QuviviqDaridorexant Hcl | 30 | $15,504 |
| Bupropion XlBupropion Hcl | 119 | $7,299 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $2,768 |
| Doxepin Hcl | 15 | $2,527 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 32 | $2,284 |
| Quetiapine Fumarate | 117 | $2,229 |
| Trazodone Hcl | 108 | $2,025 |
| Duloxetine Hcl | 87 | $1,567 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $1,524 |
| Divalproex Sodium | 26 | $1,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $795 | $101,57663 claims |
| Johnson & JohnsonSpravato | $243 | $64,13236 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $358 | $21,15911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $20,90527 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $277 | $15,50430 claims |
| Almatica Pharma LLCSertraline Hcl | $91 | $531103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,544 surgical providers in New York.
Other surgical in Manhasset
- Lindsay SchweikarthAlbany$324K
- Nicole FeinNew York$225K
- Kenneth RuizNew York$93K
- Terry LinNew York$70K
- Beth PhillipsEast Syracuse$51K
- James DoolittleNew York$46K
- Tanya GeistAmherst$43K
- Irina KommNew York$39K
- Sarah MartineckWilliamsville$34K
- Richard DalabaAlbany$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.